Iambic Therapeutics, Inc. (NASDAQ:IAM – Get Free Report)’s stock price rose 11.8% during trading on Monday. The company traded as high as $11.37 and last traded at $11.37. Approximately 165,709 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 738,781 shares. The stock had previously closed at $10.17.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on IAM. Citigroup started coverage on shares of Iambic Therapeutics in a research note on Monday. They issued a “buy” rating and a $22.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Iambic Therapeutics in a research report on Tuesday. They set a “buy” rating and a $35.00 price target for the company. Wall Street Zen upgraded shares of Iambic Therapeutics to a “hold” rating in a research note on Saturday. JPMorgan Chase & Co. started coverage on Iambic Therapeutics in a research note on Monday. They set an “overweight” rating and a $22.00 price target on the stock. Finally, Bank of America initiated coverage on shares of Iambic Therapeutics in a report on Monday. They set a “buy” rating and a $30.00 target price for the company. Four analysts have rated the stock with a Buy rating. Based on data from MarketBeat, Iambic Therapeutics currently has a consensus rating of “Buy” and an average target price of $27.25.
Check Out Our Latest Research Report on Iambic Therapeutics
Iambic Therapeutics Stock Up 31.6%
Insider Buying and Selling at Iambic Therapeutics
In other Iambic Therapeutics news, Director Evan Lockwood Rachlin purchased 718,750 shares of the stock in a transaction that occurred on Friday, October 16th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $11,500,000.00. Following the completion of the transaction, the director owned 2,588,248 shares of the company’s stock, valued at $41,411,968. The trade was a 38.45% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 22.90% of the company’s stock.
About Iambic Therapeutics
Featured Stories
- Five stocks we like better than Iambic Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
